Anticancer activities of histone deacetylase inhibitors (original) (raw)

• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70. (2000).
  CAS PubMed Google Scholar
• Kinzler, K. W. & Vogelstein, B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386, 761–763 (1997).
  CAS PubMed Google Scholar
• Lund, A. H. & van Lohuizen, M. Epigenetics and cancer. Genes Dev. 18, 2315–2335 (2004). This manuscript highlights key aspects of epigenetic gene regulation and discusses known connections between epigenetic gene (de)regulation and cancer.
  CAS PubMed Google Scholar
• Baylin, S. B. & Ohm, J. E. Epigenetic gene silencing in cancer- a mechanism for early oncogenic pathway addiction? Nature Rev. Cancer 6, 107–116 (2006).
  CAS Google Scholar
• Nightingale, K. P., O'Neill, L. P. & Turner, B. M. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr. Opin. Genet. Dev. 16, 125–136 (2006).
  CAS PubMed Google Scholar
• Roth, S. Y., Denu, J. M. & Allis, C. D. Histone acetyltransferases. Annu. Rev. Biochem. 70, 81–120 (2001).
  CAS PubMed Google Scholar
• Thiagalingam, S. et al. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. NY Acad. Sci. 983, 84–100 (2003).
  CAS PubMed Google Scholar
• Pandolfi, P. P. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother. Pharmacol. 48 (Suppl. 1), S17–S19 (2001).
  CAS PubMed Google Scholar
• Marks, P. A. & Jiang, X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 4, 549–551 (2005).
  CAS PubMed Google Scholar
• Lindemann, R. K., Gabrielli, B. & Johnstone, R. W. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3, 779–788 (2004).
  CAS PubMed Google Scholar
• Jabbour, E. J. & Giles, F. J. New agents in myelodysplastic syndromes. Curr. Hematol. Rep. 4, 191–199 (2005).
  CAS PubMed Google Scholar
• Lin, R. J., Sternsdorf, T., Tini, M. & Evans, R. M. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 20, 7204–7215 (2001).
  CAS PubMed Google Scholar
• Cote, S. et al. Response to histone deacetylase inhibition of novel PML/RARα mutants detected in retinoic acid-resistant APL cells. Blood 100, 2586–2596 (2002).
  CAS PubMed Google Scholar
• He, L. Z. et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108, 1321–1330 (2001).
  CAS PubMed PubMed Central Google Scholar
• Warrell, R. P., Jr., He, L. Z., Richon, V., Calleja, E. & Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl Cancer Inst. 90, 1621–1625 (1998).
  CAS PubMed Google Scholar
• Ferrara, F. F. et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61, 2–7 (2001). References 12–16 outline the molecular rationale for combining HDACi and retinoids.
  PubMed Google Scholar
• Pasqualucci, L. et al. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk. Lymphoma 44 (Suppl. 3), S5–S12 (2003).
  CAS PubMed Google Scholar
• Halkidou, K. et al. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59, 177–189 (2004).
  CAS PubMed Google Scholar
• Choi, J. H. et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J. Cancer Res. 92, 1300–1304 (2001).
  CAS PubMed PubMed Central Google Scholar
• Wilson, A. J. et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 281, 13548–13558 (2006).
  CAS PubMed Google Scholar
• Zhang, Z. et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res. Treat 94, 11–16 (2005).
  CAS PubMed Google Scholar
• Zhu, P. et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5, 455–463 (2004).
  CAS PubMed Google Scholar
• Huang, B. H. et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 12, 395–404 (2005).
  CAS PubMed Google Scholar
• Song, J. et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 113, 264–268 (2005).
  CAS PubMed Google Scholar
• Zhang, Z. et al. HDAC6 expression is correlated with better survival in breast cancer. Clin. Cancer Res. 10, 6962–6968 (2004).
  CAS PubMed Google Scholar
• Glaser, K. B. et al. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 310, 529–536 (2003).
  CAS PubMed Google Scholar
• Insinga, A. et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Med. 11, 71–76 (2005). Together with reference 181 demonstrated a key tumour selective role for the TRAIL (death receptor) pathway in the induction of apoptosis following treatment with HDAC inhibitors.
  CAS PubMed Google Scholar
• Fraga, M. F. et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genet. 37, 391–400 (2005). This manuscript describes the comprehensive analysis of global histone H4 modifications, and identified modification differences between normal tissues and tumor cells.
  CAS PubMed Google Scholar
• Leder, A., Orkin, S. & Leder, P. Differentiation of erythroleukemic cells in the presence of inhibitors of DNA synthesis. Science 190, 893–894 (1975).
  CAS PubMed Google Scholar
• Riggs, M. G., Whittaker, R. G., Neumann, J. R. & Ingram, V. M. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268, 462–464 (1977).
  CAS PubMed Google Scholar
• Yoshida, M., Kijima, M., Akita, M. & Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17174–17179 (1990).
  CAS PubMed Google Scholar
• Richon, V. M. et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl Acad. Sci. USA 95, 3003–3007 (1998). References 29–32 provide a historical time line of the discovery that inhibition of HDAC activity leads to tumour cell differentiation and death.
  CAS PubMed Google Scholar
• Fischle, W. et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9, 45–57 (2002).
  CAS PubMed Google Scholar
• Hu, E. et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307, 720–728 (2003).
  CAS PubMed Google Scholar
• Li, J. et al. Expression and functional characterization of recombinant human HDAC1 and HDAC3. Life Sci. 74, 2693–2705 (2004).
  CAS PubMed Google Scholar
• Furumai, R. et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62, 4916–4921 (2002).
  CAS PubMed Google Scholar
• Qian, D. Z. et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res. 12, 634–642 (2006).
  CAS PubMed Google Scholar
• Warrener, R. et al. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J. 17, 1550–1552 (2003).
  CAS PubMed Google Scholar
• Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M. & Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl Acad. Sci. USA 100, 4389–4394 (2003).
  CAS PubMed Google Scholar
• Blagosklonny, M. V. et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol. Cancer Ther. 1, 937–941 (2002).
  CAS PubMed Google Scholar
• Drummond, D. C. et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45, 495–528 (2005).
  CAS PubMed Google Scholar
• Dokmanovic, M. & Marks, P. A. Prospects: histone deacetylase inhibitors. J. Cell. Biochem. 96, 293–304 (2005).
  CAS PubMed Google Scholar
• Kelly, W. K. & Marks, P. A. Drug insight: Histone deacetylase inhibitors — development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nature Clin. Pract. Oncol. 2, 150–157 (2005). The authors provide an overview of the preclinical development of SAHA (vorinostat), one of the HDACi most advanced in clinical development.
  CAS Google Scholar
• Kelly, W. K., O'Connor, O. A. & Marks, P. A. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Investig. Drugs 11, 1695–1713 (2002).
  CAS PubMed Google Scholar
• Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Rev. Drug Discov. 1, 287–299 (2002).
  CAS Google Scholar
• Minucci, S. & Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Rev. Cancer 6, 38–51 (2006).
  CAS Google Scholar
• Willis, S. N. & Adams, J. M. Life in the balance: how BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 17, 617–625 (2005).
  CAS PubMed PubMed Central Google Scholar
• Ruefli, A. A. et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl Acad. Sci. USA 98, 10833–10838 (2001). This study identified a new mechanism for activation of the 'intrinsic' apoptotic pathway by SAHA.
  CAS PubMed Google Scholar
• Peart, M. J. et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 63, 4460–4471 (2003).
  CAS PubMed Google Scholar
• Mitsiades, N. et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101, 4055–4062 (2003).
  CAS PubMed Google Scholar
• Zhang, Y., Adachi, M., Kawamura, R. & Imai, K. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death Differ. 13, 129–140 (2006).
  CAS PubMed Google Scholar
• Zhao, Y. et al. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc. Natl Acad. Sci. USA 102, 16090–16095 (2005).
  CAS PubMed Google Scholar
• Rosato, R. R., Almenara, J. A. & Grant, S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 63, 3637–3645 (2003).
  CAS PubMed Google Scholar
• Sade, H. & Sarin, A. Reactive oxygen species regulate quiescent T-cell apoptosis via the BH3-only proapoptotic protein BIM. Cell Death Differ. 11, 416–423 (2004).
  CAS PubMed Google Scholar
• Marks, P. A., Miller, T. & Richon, V. M. Histone deacetylases. Curr. Opin. Pharmacol. 3, 344–351 (2003).
  CAS PubMed Google Scholar
• Marks, P. et al. Histone deacetylases and cancer: causes and therapies. Nature Rev. Cancer 1, 194–202 (2001).
  CAS Google Scholar
• Marks, P. A., Richon, V. M. & Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl Cancer Inst. 92, 1210–1216 (2000).
  CAS PubMed Google Scholar
• Gabrielli, B. G., Johnstone, R. W. & Saunders, N. A. Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress. Curr Cancer Drug Targets 2, 337–353 (2002).
  CAS PubMed Google Scholar
• Vrana, J. A. et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18, 7016–7025 (1999).
  CAS PubMed Google Scholar
• Richon, V. M., Sandhoff, T. W., Rifkind, R. A. & Marks, P. A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA 97, 10014–10019 (2000).
  CAS PubMed Google Scholar
• Kim, Y. B., Lee, K. H., Sugita, K., Yoshida, M. & Horinouchi, S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18, 2461–2470 (1999).
  CAS PubMed Google Scholar
• Qiu, L. et al. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell. 11, 2069–2083 (2000).
  CAS PubMed PubMed Central Google Scholar
• Sandor, V. et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br. J. Cancer 83, 817–825 (2000).
  CAS PubMed PubMed Central Google Scholar
• Glaser, K. B. et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2, 151–163 (2003).
  CAS PubMed Google Scholar
• Chen, Z. et al. Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) α and β messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett. 188, 127–140 (2002).
  CAS PubMed Google Scholar
• Jaboin, J. et al. MS-27–275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 62, 6108–6115 (2002).
  CAS PubMed Google Scholar
• Burgess, A. J. et al. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol. 60, 828–837 (2001).
  CAS PubMed Google Scholar
• Taddei, A., Roche, D., Bickmore, W. A. & Almouzni, G. The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep. 6, 520–524 (2005). Discusses the consequences of HDAC inhibition (histone hyperacetylation) on heterochromatin structure and dynamics in dividing and non-dividing cells
  CAS PubMed PubMed Central Google Scholar
• Pili, R., Kruszewski, M. P., Hager, B. W., Lantz, J. & Carducci, M. A. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res. 61, 1477–1485 (2001).
  CAS PubMed Google Scholar
• Sasakawa, Y. et al. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem. Pharmacol. 66, 897–906 (2003).
  CAS PubMed Google Scholar
• Michaelis, M. et al. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol. Pharmacol. 65, 520–527 (2004).
  CAS PubMed Google Scholar
• Rossig, L. et al. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ. Res. 91, 837–844 (2002).
  PubMed Google Scholar
• Deroanne, C. F. et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21, 427–436 (2002).
  CAS PubMed Google Scholar
• Crazzolara, R. et al. Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. Br. J. Haematol. 119, 965–969 (2002).
  CAS PubMed Google Scholar
• Kim, S. H. et al. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem. Biophys. Res. Commun. 315, 964–970 (2004).
  CAS PubMed Google Scholar
• Liu, L. T., Chang, H. C., Chiang, L. C. & Hung, W. C. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res. 63, 3069–3072 (2003).
  CAS PubMed Google Scholar
• Klisovic, D. D. et al. Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: a potential strategy for uveal melanoma. Melanoma Res. 15, 147–153 (2005).
  CAS PubMed Google Scholar
• Coradini, D. et al. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin. Cancer Res. 10, 4822–4830 (2004).
  CAS PubMed Google Scholar
• Maeda, T., Towatari, M., Kosugi, H. & Saito, H. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96, 3847–3856 (2000).
  CAS PubMed Google Scholar
• Magner, W. J. et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J. Immunol. 165, 7017–7024 (2000).
  CAS PubMed Google Scholar
• Armeanu, S. et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65, 6321–6329 (2005).
  CAS PubMed Google Scholar
• Skov, S. et al. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 65, 11136–11145 (2005). References 81 and 82 demonstrate the induction of the MHC class I-related molecules MIC-A and MIC-B selectively on tumour cells, which renders the cells susceptible to natural killer cell-mediated lysis.
  CAS PubMed Google Scholar
• Reddy, P. et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl Acad. Sci. USA 101, 3921–3926 (2004).
  CAS PubMed Google Scholar
• Nusinzon, I. & Horvath, C. M. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl Acad. Sci. USA 100, 14742–14747 (2003).
  CAS PubMed Google Scholar
• Yuan, Z. L., Guan, Y. J., Chatterjee, D. & Chin, Y. E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307, 269–273 (2005).
  CAS PubMed Google Scholar
• Chen, L., Fischle, W., Verdin, E. & Greene, W. C. Duration of nuclear NF-κB action regulated by reversible acetylation. Science 293, 1653–1657 (2001).
  CAS Google Scholar
• Johnstone, R. W. & Licht, J. D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4, 13–18 (2003).
  CAS PubMed Google Scholar
• Gu, W. & Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595–606 (1997).
  CAS PubMed Google Scholar
• Martinez-Balbas, M. A., Bauer, U. M., Nielsen, S. J., Brehm, A. & Kouzarides, T. Regulation of E2F1 activity by acetylation. EMBO J. 19, 662–671 (2000).
  CAS PubMed PubMed Central Google Scholar
• Luo, J., Su, F., Chen, D., Shiloh, A. & Gu, W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408, 377–381 (2000).
  CAS PubMed Google Scholar
• Pediconi, N. et al. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nature Cell Biol. 5, 552–558 (2003).
  CAS PubMed Google Scholar
• Costanzo, A. et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell 9, 175–186 (2002). References 91 and 92 propose that transcription factor acetylation can occur in response to DNA damage, and that these acetylated factors subsequently favour the transcription of pro-apoptotic genes without affecting the induction of other genes (for example, cell-cycle regulatory genes).
  CAS PubMed Google Scholar
• Finzer, P. et al. HDAC inhibitors trigger apoptosis in HPV-positive cells by inducing the E2F-p73 pathway. Oncogene 23, 4807–4817 (2004).
  CAS PubMed Google Scholar
• Hershko, T. & Ginsberg, D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J. Biol. Chem. 279, 8627–8634 (2004).
  CAS PubMed Google Scholar
• Chipuk, J. E. & Green, D. R. Dissecting p53-dependent apoptosis. Cell Death Differ. 13, 994–1002 (2006).
  CAS PubMed Google Scholar
• Tomita, Y. et al. WTp53 but not tumor-derived mutants bind to BCL2 via the DNA binding domain and induce mitochondrial permeabilization. J. Biol. Chem. 281, 8600–8606 (2006).
  CAS PubMed Google Scholar
• Xu, Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ. 10, 400–403 (2003).
  CAS PubMed Google Scholar
• Terui, T. et al. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res. 63, 8948–8954 (2003).
  CAS PubMed Google Scholar
• Blagosklonny, M. V. et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res. 65, 7386–7392 (2005). This study describes 'pharmacological rescue of mutant p53' by HDACi, whereby induction of a wild-type p53 transcriptional response occurred in HDACi-treated cells containing mutant p53.
  CAS PubMed Google Scholar
• Chen, C., Edelstein, L. C. & Gelinas, C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell Biol. 20, 2687–2695 (2000).
  PubMed PubMed Central Google Scholar
• Stehlik, C. et al. Nuclear factor (NF)-κB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis. J. Exp. Med. 188, 211–26 (1998).
  CAS PubMed PubMed Central Google Scholar
• Kramer, O. H. et al. Acetylation of Stat1 modulates NF-κB activity. Genes Dev. 20, 473–485 (2006).
  PubMed PubMed Central Google Scholar
• Medina, V. et al. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 57, 3697–3707 (1997).
  CAS PubMed Google Scholar
• Glick, R. D. et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res. 59, 4392–4399 (1999).
  CAS PubMed Google Scholar
• Kwon, S. H. et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem. 277, 2073–2080 (2002).
  CAS PubMed Google Scholar
• Glozak, M. A., Sengupta, N., Zhang, X. & Seto, E. Acetylation and deacetylation of non-histone proteins. Gene 363, 15–23 (2005).
  CAS PubMed Google Scholar
• Cohen, H. Y. et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 13, 627–638 (2004).
  CAS PubMed Google Scholar
• Subramanian, C., Opipari, A. W., Jr., Bian, X., Castle, V. P. & Kwok, R. P. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 4842–4847 (2005). Reference 107 identified a link between acetylation of the non-histone protein, Ku70, and induction of apoptosis; reference 108 subsequently demonstrated that Ku70 acetylation is crucial for HDACi-mediated apoptosis.
  CAS PubMed Google Scholar
• Canettieri, G. et al. Attenuation of a phosphorylation-dependent activator by an HDAC-PP1 complex. Nature Struct. Biol. 10, 175–181 (2003).
  CAS PubMed Google Scholar
• Brush, M. H., Guardiola, A., Connor, J. H., Yao, T. P. & Shenolikar, S. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. J. Biol. Chem. 279, 7685–7691 (2004).
  CAS PubMed Google Scholar
• Chen, C. S., Weng, S. C., Tseng, P. H. & Lin, H. P. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem. 280, 38879–38887 (2005).
  CAS PubMed Google Scholar
• Whitesell, L. & Lindquist, S. L. HSP90 and the chaperoning of cancer. Nature Rev. Cancer 5, 761–772 (2005).
  CAS Google Scholar
• Budillon, A., Bruzzese, F., Di Gennaro, E. & Caraglia, M. Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase. Curr. Drug Targets 6, 337–351 (2005).
  CAS PubMed Google Scholar
• Kovacs, J. J. et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18, 601–67 (2005).
  CAS PubMed Google Scholar
• Fuino, L. et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2, 971–984 (2003).
  CAS PubMed Google Scholar
• Nimmanapalli, R. et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr–Abl and induces apoptosis of imatinib mesylate-sensitive or-refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 63, 5126–5135 (2003).
  CAS PubMed Google Scholar
• Bali, P. et al. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin. Cancer Res. 10, 4991–4997 (2004).
  CAS PubMed Google Scholar
• Yu, X. et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl Cancer Inst. 94, 504–513 (2002).
  CAS PubMed Google Scholar
• Hideshima, T. et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl Acad. Sci. USA 102, 8567–8572 (2005).
  CAS PubMed Google Scholar
• Bali, P. et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280, 26729–26734 (2005).
  CAS PubMed Google Scholar
• Bhalla, K. N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. 23, 3971–3993 (2005).
  CAS PubMed Google Scholar
• Reynolds, C. P. & Lemons, R. S. Retinoid therapy of childhood cancer. Hematol. Oncol. Clin. North Am. 15, 867–910 (2001).
  CAS PubMed Google Scholar
• Coffey, D. C. et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. 61, 3591–3594 (2001).
  CAS PubMed Google Scholar
• Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G. & Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet. 21, 103–107 (1999). This paper described functional synergy between HDACi and demethylation agents in reactivating epigenetically silenced genes, and demonstrated the hierarchical nature of epigenetic gene silencing in cancer.
  CAS PubMed Google Scholar
• Gore, S. D. et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 66, 6361–6369 (2006).
  CAS PubMed Google Scholar
• Kim, M. S. et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 63, 7291–7300 (2003).
  CAS PubMed Google Scholar
• Catley, L. et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102, 2615–2622 (2003).
  CAS PubMed Google Scholar
• Chauhan, D. et al. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J. Biol. Chem. 276, 24453–24456 (2001).
  CAS PubMed Google Scholar
• Loprevite, M. et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol. Res. 15, 39–48 (2005).
  CAS PubMed Google Scholar
• Pauer, L. R. et al. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest. 22, 886–896 (2004).
  CAS PubMed Google Scholar
• Zhang, X. D., Gillespie, S. K., Borrow, J. M. & Hersey, P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol. Cancer Ther. 3, 425–435 (2004).
  CAS PubMed Google Scholar
• Nakata, S. et al. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23, 6261–6271 (2004).
  CAS PubMed Google Scholar
• Inoue, S. et al. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 11 (Suppl. 2), S193–S206 (2004).
  CAS PubMed Google Scholar
• Rosato, R. R., Almenara, J. A., Dai, Y. & Grant, S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2, 1273–1284 (2003).
  CAS PubMed Google Scholar
• Guo, F. et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 64, 2580–2589 (2004).
  CAS PubMed Google Scholar
• Singh, T. R., Shankar, S. & Srivastava, R. K. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24, 4609–4623 (2005).
  CAS PubMed Google Scholar
• Watanabe, K., Okamoto, K. & Yonehara, S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ. 12, 10–18 (2005).
  CAS PubMed Google Scholar
• Kim, E. H. et al. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 24, 6877–6889 (2005).
  CAS PubMed Google Scholar
• Earel, J. K., Jr., VanOosten, R. L. & Griffith, T. S. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 66, 499–507 (2006).
  CAS PubMed Google Scholar
• Rosato, R. R., Almenara, J. A., Yu, C. & Grant, S. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol. Pharmacol. 65, 571–581 (2004).
  CAS PubMed Google Scholar
• Rahmani, M. et al. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. Oncogene 22, 6231–6242 (2003).
  CAS PubMed Google Scholar
• Yu, C., Dasmahapatra, G., Dent, P. & Grant, S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia 19, 1579–1589 (2005).
  CAS PubMed Google Scholar
• Deininger, M., Buchdunger, E. & Druker, B. J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640–2653 (2005).
  CAS PubMed Google Scholar
• Yu, C. et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and-resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res. 63, 2118–2126 (2003).
  CAS PubMed Google Scholar
• Nimmanapalli, R., Fuino, L., Stobaugh, C., Richon, V. & Bhalla, K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101, 3236–3239 (2003).
  CAS PubMed Google Scholar
• Kim, J. S. et al. Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades. Br. J. Haematol. 124, 166–178 (2004).
  CAS PubMed Google Scholar
• George, P. et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105, 1768–1776 (2005).
  CAS PubMed Google Scholar
• Kawano, T. et al. Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect. Anticancer Res. 24, 2705–2712 (2004).
  CAS PubMed Google Scholar
• Rahmani, M. et al. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res. 63, 8420–8427 (2003).
  CAS PubMed Google Scholar
• Rahmani, M. et al. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol. Pharmacol. 67, 1166–1176 (2005).
  CAS PubMed Google Scholar
• Yu, C. et al. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102, 3765–3774 (2003).
  CAS PubMed Google Scholar
• Pei, X. Y., Dai, Y. & Grant, S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res. 10, 3839–3852 (2004).
  CAS PubMed Google Scholar
• Adachi, M. et al. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells. Clin. Cancer Res. 10, 3853–3862 (2004).
  CAS PubMed Google Scholar
• Nawrocki, S. T. et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 66, 3773–3781 (2006).
  CAS PubMed Google Scholar
• Wang, X. et al. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-κB pathway. Cancer Res. 66, 1089–1095 (2006).
  CAS PubMed Google Scholar
• Kawaguchi, Y. et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115, 727–738 (2003). This study identified HDAC6 as a key component of the aggresome and describes a functional role for HDAC6 in the clearance of misfolded protein aggregates.
  CAS PubMed Google Scholar
• Kopito, R. R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 10, 524–530 (2000).
  CAS PubMed Google Scholar
• Zhang, Y., Jung, M. & Dritschilo, A. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat. Res. 161, 667–674 (2004).
  CAS PubMed Google Scholar
• Kim, J. H., Shin, J. H. & Kim, I. H. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 59, 1174–1180 (2004).
  CAS PubMed Google Scholar
• Camphausen, K., Scott, T., Sproull, M. & Tofilon, P. J. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin. Cancer Res. 10, 6066–6071 (2004).
  CAS PubMed Google Scholar
• Camphausen, K. et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int. J. Cancer 114, 380–36 (2005).
  CAS PubMed Google Scholar
• Nome, R. V. et al. Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death. Mol. Cancer Ther. 4, 1231–1238 (2005).
  CAS PubMed Google Scholar
• Karagiannis, T. C., Kn, H. & El-Osta, A. The Histone Deacetylase Inhibitor, Trichostatin A, Enhances Radiation Sensitivity and Accumulation of γH2A. X. Cancer Biol. Ther. 4, 787–793 (2005).
  CAS PubMed Google Scholar
• Shiloh, Y. ATM and related protein kinases: safeguarding genome integrity. Nature Rev. Cancer 3, 155–168 (2003).
  CAS Google Scholar
• Bakkenist, C. J. & Kastan, M. B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421, 499–506 (2003).
  CAS PubMed Google Scholar
• Kim, G. D. et al. Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. J. Biol. Chem. 274, 31127–31130 (1999).
  CAS PubMed Google Scholar
• Munshi, A. et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 11, 4912–4922 (2005).
  CAS PubMed Google Scholar
• Yaneva, M., Li, H., Marple, T. & Hasty, P. Non-homologous end joining, but not homologous recombination, enables survival for cells exposed to a histone deacetylase inhibitor. Nucleic Acids Res. 33, 5320–5330 (2005).
  CAS PubMed PubMed Central Google Scholar
• Chung, Y. L., Wang, A. J. & Yao, L. F. Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. Mol. Cancer Ther. 3, 317–325 (2004).
  CAS PubMed Google Scholar
• Vannini, A. et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl Acad. Sci. USA 101, 15064–15069 (2004).
  CAS PubMed Google Scholar
• Hubbert, C. et al. HDAC6 is a microtubule-associated deacetylase. Nature 417, 455–458 (2002).
  CAS PubMed Google Scholar
• Gao, L., Cueto, M. A., Asselbergs, F. & Atadja, P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277, 25748–25755 (2002).
  CAS PubMed Google Scholar
• Johnstone, R. W., Ruefli, A. A. & Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153–164 (2002).
  CAS PubMed Google Scholar
• Cory, S. & Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch. Nature Rev. Cancer 2, 647–656 (2002).
  CAS Google Scholar
• Cory, S., Huang, D. C. & Adams, J. M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22, 8590–8607 (2003).
  CAS PubMed Google Scholar
• Butler, L. M. et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res. 7, 962–970 (2001).
  CAS PubMed Google Scholar
• Park, J. H. et al. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res. 10, 5271–5281 (2004).
  CAS PubMed Google Scholar
• Furumai, R. et al. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl Acad. Sci. USA 98, 87–92 (2001).
  CAS PubMed Google Scholar
• Kwon, H. J., Owa, T., Hassig, C. A., Shimada, J. & Schreiber, S. L. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl Acad. Sci. USA 95, 3356–3361 (1998).
  CAS PubMed Google Scholar
• Imai, T. et al. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene 22, 9231–9242 (2003).
  CAS PubMed Google Scholar
• Nebbioso, A. et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Med. 11, 77–84 (2005).
  CAS PubMed Google Scholar
• Sutheesophon, K. et al. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). J. Cell Physiol. 203, 387–397 (2005).
  CAS PubMed Google Scholar
• Bernhard, D. et al. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. FASEB J. 13, 1991–2001 (1999).
  CAS PubMed Google Scholar
• Rosato, R. R. et al. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol. Pharmacol. 69, 216–225 (2006).
  CAS PubMed Google Scholar
• Mitsiades, C. S. et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl Acad. Sci. USA 101, 540–545 (2004).
  CAS PubMed Google Scholar
• Peart, M. J. et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 102, 3697–3702 (2005).
  CAS PubMed Google Scholar
• Moore, P. S. et al. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim. Biophys. Acta 1693, 167–176 (2004). References 185–187 describe gene-expression profiling analyses of tumour cell lines, undertaken to identify genes that are regulated by structurally diverse HDACi.
  CAS PubMed Google Scholar
• Duan, H., Heckman, C. A. & BOX er, L. M. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol. Cell Biol. 25, 1608–1619 (2005).
  CAS PubMed PubMed Central Google Scholar
• Tan, J. et al. Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor- induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. J. Biol. Chem. 281, 10508–10515 (2006).
  CAS PubMed Google Scholar
• Rahmani, M. et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res. 65, 2422–2432 (2005).
  CAS PubMed Google Scholar
• Ungerstedt, J. S. et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 673–678 (2005).
  CAS PubMed Google Scholar
• Butler, L. M. et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl Acad. Sci. USA 99, 11700–11705 (2002).
  CAS PubMed Google Scholar
• Zhu, W. G. & Otterson, G. A. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anti-Canc Agents 3, 187–199 (2003).
  CAS Google Scholar
• Keen, J. C. et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res. Treat 81, 177–186 (2003).
  CAS PubMed Google Scholar
• Shaker, S., Bernstein, M., Momparler, L. F. & Momparler, R. L. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk. Res. 27, 437–444 (2003).
  CAS PubMed Google Scholar
• Klisovic, M. I. et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17, 350–358 (2003).
  CAS PubMed Google Scholar
• Boivin, A. J., Momparler, L. F., Hurtubise, A. & Momparler, R. L. Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs 13, 869–874 (2002).
  CAS PubMed Google Scholar
• Minucci, S. et al. A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc. Natl Acad. Sci. USA 94, 11295–11300 (1997).
  CAS PubMed Google Scholar
• Kitazono, M., Bates, S., Fok, P., Fojo, T. & Blagosklonny, M. V. The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53. Cancer Biol. Ther. 1, 665–668 (2002).
  CAS PubMed Google Scholar
• Zhang, X. D., Gillespie, S. K., Borrow, J. M. & Hersey, P. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem. Pharmacol. 66, 1537–1545 (2003).
  CAS PubMed Google Scholar
• Nguyen, D. M. et al. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin. Cancer Res. 10, 1813–1825 (2004).
  CAS PubMed Google Scholar
• Rosato, R. R., Wang, Z., Gopalkrishnan, R. V., Fisher, P. B. & Grant, S. Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int. J. Oncol. 19, 181–191 (2001).
  CAS PubMed Google Scholar
• Almenara, J., Rosato, R. & Grant, S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16, 1331–1343 (2002).
  CAS PubMed Google Scholar
• Dai, Y., Rahmani, M., Dent, P. & Grant, S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-κB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol. Cell Biol. 25, 5429–5444 (2005).
  CAS PubMed PubMed Central Google Scholar
• Garcia-Manero, G. et al. A Phase I study of the histone deacetylase inhibitor MGCD0103 (MG-0103) given as a three-times weekly oral dose in patients with leukemia or myelodysplastic syndromes (MDS). Blood 106 A4639 (2005).
  Google Scholar